Identification and characterization of interferon signaling-related microRNAs in occult hepatitis B virus infection

Yiying Wang1,2†, Peifu Zhu3†, Jing Qiu1, Jie Wang1, Huijuan Zhu1, Yinwei Zhu1, Lige Zhang1, Jie Zhu1, Xingxiang Liu4 and Chen Dong1*

Abstract

Background: Occult hepatitis B virus infection (OBI) is an important risk factor of liver cirrhosis and hepatocellular carcinoma. Type 1 interferon (IFN) signaling-related miRNAs were significantly associated with hepatitis B virus (HBV) infection. However, the characteristics of serum IFN signaling-related miRNAs in OBI remain unclear. Therefore, this study aimed to analyze the expression levels of serum IFN signaling-related miRNAs in OBI and to evaluate their potential values for OBI diagnosis.

Methods: Twenty serum samples for training test (10 healthy controls and 10 OBI patients) and 438 validation serum samples from healthy controls, asymptomatic HBsAg carriers (ASC), and chronic hepatitis B (CHB) and OBI patients were collected. Expression levels of 32 IFN signaling-related miRNAs were analyzed in training and validation sets of samples using RT-qPCR.

Results: Among 32 IFN signaling-related miRNAs, decreased miR-122 levels and increased miR-130a levels were detected in training OBI samples. Furthermore, the results from validation test showed that the mean serum miR-122 and miR-130a level was 2.28 ± 0.96 and 3.11 ± 0.93 in OBI subjects, respectively. Compared to the healthy controls, ASC and CHB patients, miR-122 levels were significantly downregulated, while miR-130a levels were significantly upregulated in OBI patients. ROC analysis indicated that miR-122 + miR-130a could differentiate OBI from healthy controls, ASC, and CHB (≥0.87 of AUC).

Conclusions: Our study suggested that decreased serum miR-122 level and increased miR-130a level were significantly associated with OBI. Moreover, a combination of miR-122 and miR-130a could be served as a potential marker for OBI diagnosis.

Background

Worldwide, hepatitis B virus (HBV) infection remains a major public health issue, with more than 350 million people chronically infected. Infection by HBV can be divided into five clinical categories: asymptomatic, acute, chronic, fulminant, and occult HBV infection (OBI). OBI has been defined as the “presence of HBV viral DNA in the liver (with or without detectable HBV DNA in serum) of HBsAg-negative individuals tested with the currently available serum assays” [1]. Although the mechanism of OBI development is not fully understood, it has been considered that OBI is significantly associated with the pathogenesis of cryptogenic liver disease and increases the risks for liver cirrhosis and hepatocellular carcinoma (HCC) [2, 3].

MicroRNAs (miRNAs) are small ~22 nucleotide non-coding RNAs that downregulate gene expression by mRNA degradation or translational repression. Cellular miRNAs can participate in most cellular processes, including cell growth, differentiation, apoptosis, immune reaction, and tumorigenesis [4, 5]. Because most miRNAs are
highly stable in circulation and their expression patterns seem to be tissue-specific, serum miRNAs are emerged as new biomarker candidates for the diagnosis of both communicable and non-communicable diseases [6–8].

Endogenous interferons (IFNs) are antiviral and immunomodulatory cytokines that trigger the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway with subsequent induction of IFN-stimulated genes (ISGs) [9]. Recently, a growing body of evidences has demonstrated that RNA interference through miRNAs is an inherent component of the IFN-antiviral arsenal [10, 11]. In a multicenter retrospective study, Lin et al. reported that IFN signaling-related miRNAs such as miR-29 family, miR-130a, miR-143, and miR-145 could be used as serum markers for the early screening of HBV-related HCC [12]. Additionally, the previous studies have shown that miR-122, miR-125b, miR-372/373, and miR-146 could influence HBV replication in vitro and were significantly associated with HBV-related cirrhosis and HCC [13, 14].

Considering that type I IFN signaling plays a critical role in HBV infections, we conducted the present study to analyze the expression profiles of serum IFN signaling-related miRNAs in OBI patients and to evaluate their potential values for OBI diagnosis.

Methods
Study population
This study was approved by ethics committee of Huai’an Fourth Hospital, Huai’an, China, and written informed consent was obtained from each participant (Ethics Certification Number: hasy/2016ky002). Totally, 117 healthy controls, 107 asymptomatic HBsAg carriers (ASC), 115 CHB patients, and 119 OBI patients were recruited from Huai’an Fourth Hospital and Zhangjiagang First People Hospital, respectively. The diagnosis of ASC, CHB, and OBI was based on the “Guidelines for prevention and treatment of chronic hepatitis B, China (2015)” [15]. Participants who had coinfection with human immunodeficiency virus or hepatitis C virus (HCV), autoimmune hepatitis, drug-induced injury, or alcohol abuse were excluded. In addition, we excluded the participants diagnosed with liver cirrhosis or carcinoma in the present study.

Serum samples preparation
Eight milliliters of fasting blood sample was collected from each participant during his/her first admission to the hospital. Cellular components were removed by two consecutive centrifugation steps (1500 g for 10 min at 4 °C and 2000 g for 3 min at 4 °C, respectively). The supernatant serum was recovered and then stored at –80 °C.

Serum RNA extraction
Total RNA was isolated from 300 μL serum with commercial RNA extraction and purification kit (MACHEREY-NAGEL SA, France) according to the manufacturer’s protocol. In order to warrant the consistency in the experimental procedures, exogenous cel-miR-39 was spiked into each serum sample before RNA extraction and then used as an internal control for normalizing miRNA expression level. The concentration of RNA was measured at OD260/280 by a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, Delaware).

Reverse transcription, real-time quantitative PCR analysis of miRNAs
Reverse transcription was performed with “TaqMan® Advanced miRNA cDNA Synthesis kit” (Applied Biosystems). The reaction system contained 1.5 μg of total small RNA, 1.2 μl miRNA-RT primers (1 μM), 10 nmol dNTP Mix, and 0.2 μM MMLV reverse transcriptase. TaqMan probe-based microRNA assays (Applied Biosystems) were used to quantify the serum levels of miRNAs in a Q6 Real-Time System (Applied Biosystems) according to the manufacturer’s protocols. As described above, cel-miR-39 TaqManVR miRNA assay (Applied Biosystems) was selected as endogenous control for miRNA expression analysis. The cycle threshold (CT value) was defined as the number of cycles required for the fluorescent signal to cross the threshold in quantitative PCR. The expression of miRNA relative to cel-miR-39 miRNA was reported as dCT (ΔCT), which was calculated by subtracting the Ct of cel-miR-39 from the Ct of target miRNA. The relative quantitative of each sample was expressed as log₂ΔCT.

Training phase and validation phase study
Totally, 32 miRNAs (Additional file 1: Table S1) which reported to be associated with IFN signaling and HBV infection were selected in the present study. These selected miRNAs were firstly measured using real-time qRT-PCR on a training set of serum samples consisting of ten OBI patients and ten healthy controls. Those up- or downregulated miRNAs in serum (>2-fold changes) were further validated in another set of serum samples from 107 healthy controls, 107 ASC, 115 CHB patients, and 109 OBI patients.

Statistical analysis
Data are presented as means ± SD for skewed quantitative data and proportions for categorical data as indicated. Comparisons of differences in the categorical data between groups were performed using χ² test or Fisher’s exact test. Student’s t test or one-way ANOVA test was used to analyze continuous variables where appropriate. Pearson’s correlation coefficient analysis was used to evaluate serum IFN signaling-related miRNAs associated
with the clinical parameters. Receiver operating characteristic (ROC) and the area under the curve (AUC) were used to calculate the diagnostic values of the examined miRNAs. All statistical tests were two-tailed and a probability level of \( P < 0.05 \) was considered as statistically significant. Data were analyzed using SAS 9.4 software (SAS Institute, Cary, NC, USA).

## Results

### Demographic and clinical characteristics

The demographic and clinical characteristics of the healthy controls, ASC, CHB, and OBI patients were summarized in Table 1. There were no differences in age and gender among four groups. OBI patients were negative to HBsAg, while ASC individuals and CHB patients were positive to HBsAg. In addition, participants in CHB groups had higher AST and ALT activities than those in healthy controls, ASC group, and OBI group. Compared to the participants with CHB, the lower viral DNA load was detected in OBI subjects.

### Serum IFN signaling-related miRNAs selection in a training set of serum samples

We firstly performed the qRT-PCR assay to examine the expression levels of 32 IFN signaling-related miRNAs in the training samples (10 OBI patients and 10 healthy controls). The mean ratio of OBI vs. HC in training samples is shown in Fig. 1. Mean ratio value < 1.0: downregulated; mean ratio value > 1.0: upregulated; mean ratio value = 1.0: no changes.

### Table 1 Demographic characteristics of the healthy controls and OBI, ASC and CHB patients

| Variable | HC \( N = 117 \) | OBI \( N = 119 \) | ASC \( N = 107 \) | CHB \( N = 115 \) | \( \chi^2 \)/F | \( P \) value | \( \chi^2 \)/F | \( P \) value\(^a\) |
|----------|----------------|----------------|----------------|----------------|--------------|------------|--------------|------------|
| Age (year) | 45.58 ± 13.08 | 42.30 ± 13.60 | 44.19 ± 15.00 | 44.40 ± 13.10 | 1.16 | 0.3246 | – | – |
| Gender (male) | Male:76 | Male:84 | Male:76 | Male:78 | 1.26 | 0.7380 | 0.27 | 0.602 |
| BMI (kg/m²) | 24.83 ± 3.04 | 24.48 ± 2.94 | 24.64 ± 4.50 | 24.38 ± 2.90 | 0.39 | 0.7629 | 0.39 | 0.763 |
| ALT (IU/L) | 22.35 ± 11.94 | 24.68 ± 11.33 | 28.42 ± 17.97 | 99.05 ± 69.47 | 115.24 | < .0001 | 115.87 | 0.000 |
| AST (IU/L) | 29.36 ± 13.81 | 28.31 ± 12.28 | 29.08 ± 14.47 | 115.52 ± 107.60 | 70.70 | < .0001 | 71.06 | 0.000 |
| Anti-HBs(positive) | Positive:64 | Positive:20 | Positive:25 | Positive:13 | 67.46 | < .0001 | 41.31 | 0.000 |
| WBC (10⁹/L) | 5.03 ± 1.69 | 5.25 ± 1.92 | 4.97 ± 1.62 | 4.84 ± 1.78 | 1.13 | 0.3347 | 1.08 | 0.358 |
| LYM (10⁹/L) | 34.11 ± 8.98 | 33.49 ± 9.28 | 34.86 ± 8.82 | 33.22 ± 9.62 | 0.70 | 0.5519 | 0.84 | 0.472 |
| HBV-DNA (IU/ML) | ND\(^a\) | 2.43 ± 1.34 | 2.49 ± 2.14 | 4.20 ± 2.28 | 30.31 | < .0001 | 30.12 | 0.000 |
| Genotype | Type B(15) | Type B(15) | Type B(27) | Type C(83) | Type C(88) | Type C(88) | Type B&C(3) | Type B&C(1) |
| ND\(^a\)(18) | ND\(^a\)(3) |

\( \text{ND} \) not detected, WBC white blood cell count, LYM lymphocyte count, HC healthy controls, OBI occult hepatitis B virus infection, ASC asymptomatic HBsAg carriers, CHB chronic hepatitis B

\( \text{ND} \) not detected, WBC white blood cell count, LYM lymphocyte count, HC healthy controls, OBI occult hepatitis B virus infection, ASC asymptomatic HBsAg carriers, CHB chronic hepatitis B

\(^a\)\( P \) value was adjusted for age
controls). The results showed that serum miR-122 was significantly downregulated, while miR-130a was obviously upregulated in OBI patients when compared with healthy controls (>2-fold changes. Fig. 1 and Additional file 1: Table S1). No significant differences were observed in the levels of miR-101, miR-145, miR-146a, miR-21, miR-221, miR-222, miR-373, miR-100, miR-142, miR-484, miR-125b, miR-203, miR-660, miR-150, and miR-148a between OBI patients and healthy controls. Additionally, the remained 15 IFN signaling-related miRNAs could not be successfully detected in the serum samples. Therefore, we selected miR-122 and miR-130a as candidate miRNAs for further validation study.

Serum IFN signaling-related miRNAs in OBI patients validated by qRT-PCR

As the results shown in validated study (Fig 2), the mean serum miR-122 level was 2.28 ± 0.96, 3.16 ± 4.85, 3.00 ± 0.67, and 3.61 ± 0.76 in the groups of OBI, healthy controls, ASC, and CHB, respectively. The levels of serum miR-122 were gradually increased from OBI subjects to healthy control, ASC, and CHB patients (Trends F = 4.00 and P = 0.046). In contrast, the mean serum miR-130a level was 3.11 ± 0.93 in OBI subjects, which was significantly higher than those in healthy controls (1.60 ± 0.57) and ASC (2.30 ± 0.63) and CHB (2.72 ± 0.60) patients. The levels of serum miR-130a were gradually decreased from OBI subjects to CHB patients, ASC individuals, and healthy controls (Trends F = 48.23 and P < 0.001).

Relationship of serum miRNAs with demographic and clinical parameters

In the present study, we further analyzed the associations of serum miR122 and miR-130a levels with demographic and clinical parameters. The results showed that serum miR-122 was significantly correlated with HBV DNA level. Additionally, serum miR-130a was significantly correlated with AST and ALT levels. However, there were no significant associations between serum miR-130a or miR-122 and other demographic and clinical parameters (Table 2).

Diagnostic value of serum IFN signaling-related miRNAs for OBI

According to the results presented above, we further tested whether serum miR-122 and miR-130a alone or in combination could differentiate OBI from healthy control, ASC, and CHB patients. The results of ROC analysis showed that as a single marker, miR-122 had the comparable AUC, sensitivity, and specificity to differentiate OBI from other groups (Table 3). Moreover, the ROC curve for miR-122 combination with miR-130a resulted in the highest AUC (0.93 for OBI vs. healthy controls, 0.87 for OBI vs. ASC, and 0.90 for OBI vs. CHB) (Fig. 3 and Table 3). Therefore, it suggested that serum miR-122 combined

Table 2 Associations of serum miR-122 and miR-130a levels with the demographic and clinical parameters

| Variables       | miR-122 | P value | miR-130a | P value |
|-----------------|---------|---------|----------|---------|
| Age             | −0.16   | 0.1021  | 0.09     | 0.3638  |
| Male gender (%) | 0.07    | 0.1746  | 0.05     | 0.2748  |
| BMI             | −0.12   | 0.2183  | 0.02     | 0.8493  |
| AST             | 0.08    | 0.1126  | 0.13     | 0.0007  |
| ALT             | 0.07    | 0.1628  | 0.16     | 0.0007  |
| HBV DNA        | 0.45    | <.0001  | −0.03    | 0.7904  |
with miR-130a could be used as a potential marker for OBI diagnosis.

**Discussion**

Although the relationships between serum miRNAs and HBV-related diseases, such as cirrhosis and HCC have been widely investigated previously [12], the information about the characteristics of serum IFN signaling-related miRNAs in OBI patients is limited. In the present study, we observed that serum miR-122 was apparently downregulated, while miR-130a was significantly upregulated in the patients with OBI. Moreover, the combination of serum miR-122 and miR-130a clearly separated the OBI patients from healthy controls and ASC and CHB patients with satisfied specificity and sensitivity.

MiR-122 is a liver-specific microRNA that is involved in a complex signaling network in the biological processes of liver development and differentiation, hepatic lipid metabolism, stress responses, and HCC [16–19]. The results from a Chinese study indicated that silence of miR-122 in HBV transfected Huh-7 cells with antisense miR-122 significantly increased HBsAg and HBeAg secretion [20]. Additionally, Gao et al. observed that suppression of miR-122 induced by HBV infection led to the inactivation of IFN expression, which in turn enhanced HBV replication in Huh7 cells [21]. However, Qiu et al. reported that overexpression of miR-122 could decrease the levels of heme oxygenase-1 (HO-1), while miR-122 inhibitors could increase HO-1 levels. Moreover, overexpression of HO-1 in HepG2 cells could significantly inhibit HBV replication in vitro [22, 23]. In the present study, we observed that serum miR-122 level decreased significantly in the patients with OBI compared to those with ASC and CHB and healthy control. Therefore, in order to unravel the complicated associations between miR-122 and HBV infection, more studies should be performed on this issue in the future.

Our present results showed that serum miR-130a levels were significantly higher in OBI patients than those in healthy controls and ASC and CHB patients. In the previous study, Huang et al. reported that miR-130a attenuated the replication of different genotypes of HBV DNA by reducing HBV transcription and protein synthesis in HBV-replicating hepatocytes [24]. In support of these findings, the results from a Chinese study suggested that overexpression of miR-130a results in increased expression of IFN-α/IFN-β and the IFN-stimulated genes, including MxA, ISG15, and USP18. Moreover, HCV replication was inhibited by miR-130a.
through restoring type I IFN production [25]. Taken together, we hypothesized that overexpression of miR-130a might be induced by HBV infection and that the increased miR-130a would inhibit HBV replication in the patients with OBI. However, the infection might become chronic if miR-130a could not be successfully stimulated. However, this hypothesis needs to be carefully verified in the future.

Conclusions
In conclusion, our present study identified that decreased serum miR-122 level and increased miR-130a level were significantly associated with OBI. Moreover, the combination of miR-122 and miR-130a clearly separated OBI subjects from healthy controls, ACS individuals, and CHB patients. More studies focusing on the miRNA-associated pathogenesis of HBV infection are required in the future to further understand the complex relationships between OBI and serum IFN signaling-related miRNAs.

Additional file

Additional file 1: Table S1. Expression characteristics of selected miRNAs. (XLSX 11 kb)

Abbreviations
ASC: Asymptomatic HBsAg carriers; CHB: Chronic hepatitis B; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; IFN: Type 1 interferon; miRNAs: MicroRNAs; OBI: Occult hepatitis B virus infection

Acknowledgements
This work was supported by the project sponsored by SRF for ROCS, SEM (K513901814), the Soochow University High-level Scientific Research Foundation for the introduction talent (Q413900612), Pre-research Foundation for Nature Science of Soochow University (Q313904713), and Research Foundation for the Prevention Medicine in Jiangsu province (Y2012024).

Funding
This work was funded by the Ministry of Education of the People’s Republic of China (K513901814), Pre-research Foundation for Nature Science of Soochow University (Q313904713), and Research Foundation for the Prevention Medicine in Jiangsu province (Y2012024).

Availability of data and materials
The data and material included in the present study could be provided by Chen Dong (cdong@suda.edu.cn) and Yiying Wang (w18351086056@126.com).

Authors’ contributions
The present study was designed by CD. YW, PZ, JQ, JW, HZ, YZ, LZ, JZ, and XL conducted the field survey and data collection. YW performed the data analysis and prepared the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the ethics committee of Huai’an Fourth Hospital, Huai’an, China (Ethics Certification Number: hasy/2016kly002), and written informed consent was obtained from each participant.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Epidemiology and Statistics, School of Public Health, Jiangsu Key Laboratory and Translational Medicine for Geriatric Disease, Medical College of Soochow University, 199 Renai Road, Suzhou, Jiangsu 215123, China. 2Guizhou Center for Disease Control and Prevention, Guizhou, China. 3Zhangjiagang First People Hospital, Suzhou, China. 4China Huai’an Fourth Hospital, Huai’an, China.

Received: 9 June 2017 Accepted: 7 September 2017

References
1. Raimondo G, et al. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris). 2010;58(4):254–7.
2. Wong DK, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54(3):829–36.
3. Ikeda K, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat. 2009;16(8):437–43.
4. Friedman RC, et al. Most mammalian miRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.
5. Lendvai G, et al. Alterations in microRNA expression patterns in liver diseases. On Heal. 2010;15(45):1843–53.
6. Macha MA, et al. MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des. 2014;20(33):5287–97.
7. De Guire V, et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem. 2013;46(10–11):846–60.
8. Cheng C. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.
9. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. 2010;43(3):204–9.
10. Chen Y, et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog. 2013;9(4):e1003248.
11. David M, Interferons and microRNAs. J Interf Cytokine Res. 2013;33(11):825–8.
12. Tan Y, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9(9):e107986.
13. Naito Y, Tanaka Y, Ochiya T. MicroRNAs and hepatitis B. Adv Exp Med Biol. 2015;888:389–99.
14. Liu Y, et al. Altered expression profiles of microRNAs in a stable hepatitis B virus-expressing cell line. Chin Med J. 2009;122(11):10–4.
15. Hsu JL, Iai W. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Gan Zang Bing Za Zhi. 2015;23(12):888–905.
16. Laudadio I, et al. A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. Gastroenterology. 2012;142(1):119–29.
17. Benatti RO, et al. Maternal high-fat diet consumption modulates hepatic lipid metabolism and microRNA-122 (miR-122) and microRNA-370 (miR-370) expression in offspring. Br J Nutr. 2014;111(12):2112–22.
18. Xu Y, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011;310(2):160–9.
19. Waidmann O, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat. 2012;19(2):58–65.
20. Zhu L, et al. Effects of miR-122 on expression of hepatitis B virus proteins. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011;40(6):593–7.
21. Gao D, et al. Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus. Antivir Res. 2015;118:20–8.
22. Qu L, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun. 2010;398(4):771–7.

Note
23. Shen YM, et al. Dynamic correlation between induction of the expression of heme oxygenase-1 and hepatitis B viral replication. Mol Med Rep. 2015;11(6):4706–12.

24. Huang JY, et al. MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1alpha and PPARgamma. RNA. 2015;21(3):385–400.

25. Li S, et al. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat. 2014;21(2):121–8.